Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) agreed to renew its trademark license agreement with the Shandong Xinhua Pharmaceutical Branch of Hualu Holdings for the full year 2025, a Tuesday Hong Kong bourse filing said.
The company has been using the trademark Xinhua and as it still plans to do so in the future, it agreed to renew the license agreement with the other party.
Under the renewed agreement, the company will pay 10 million yuan in annual license fee to the other party for the exclusive right to use the Trademark.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。